Acromegaly Clinical Trial
Official title:
Cardiac Structure and Function in Acromegalic Patients: A Cardiac Magnetic Resonance Imaging Study
In this study, the investigators will evaluate the cardiac structure and function, focusing
on the myocardial water content and interstitial fibrosis, in patients with active acromegaly
in comparison with 1) healthy volunteers, 2) the same acromegalic patients that have received
efficient therapy.
The investigators hypothesize that the myocardial water content in acromegaly is increased as
these patients present with sodium and water retention and that this myocardial water
infiltration will improve with efficient treatment of the disease. They will thus assess
using CMRI, this parameter by measuring the myocardial transverse relaxation time (T2),
reflecting water content in the myocardium.
Patients with acromegaly have left ventricular (LV) hypertrophy and dysfunction on
echocardiography, but only very few studies have been performed using cardiac magnetic
resonance imaging (CMRI), currently the reference modality is assessment in cardiac geometry
function. In addition, no data are available on right ventricular (RV) and atrial structure
and function. The pathophysiology of the cardiac involvement in acromegaly may be related to
increase myocardiac water content and/or interstitial myocardiac fibrosis.
The main objective of sthe study is to compare the myocardial water content in patients with
acromegaly and in healthy volunteers. Secondary objectives of the study are to evaluate :
1. interstitial fibrosis and the structure and the function of LV and RV in acromegalic
patients in comparison with healthy volunteers;
2. the reversibility of the cardiac involvement (water content, fibrosis, LV and RV
structure and function) after efficient treatment of acromegaly;
3. the elasticity of aorta in acromegalic patients in comparison with healthy volunteers
and with the post-treatment state. Twenty acromegalic patients will be included in order
to dispose of 15 patients that will completed the study and the same number of age- and
BMI-adjusted healthy volunteers will be included.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06344650 -
Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. Cross-sectional and Prospective Study
|
||
| Active, not recruiting |
NCT02092129 -
Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly.
|
N/A | |
| Completed |
NCT02012127 -
Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
|
||
| Active, not recruiting |
NCT01265121 -
Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.
|
N/A | |
| Terminated |
NCT00765323 -
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
|
Phase 3 | |
| Completed |
NCT00531908 -
Physiopathology of Sodium Retention in Acromegaly
|
N/A | |
| Completed |
NCT00500227 -
Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
|
||
| Completed |
NCT01278342 -
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
|
Phase 4 | |
| Active, not recruiting |
NCT01809808 -
A Prospective Study of Outcome After Therapy for Acromegaly
|
||
| Completed |
NCT00145405 -
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
|
Phase 4 | |
| Completed |
NCT00210457 -
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
|
Phase 3 | |
| Recruiting |
NCT05401084 -
Diet in the Management of Acromegaly
|
N/A | |
| Recruiting |
NCT00005100 -
Measurement of Outcome of Surgical Treatment in Patients With Acromegaly
|
N/A | |
| Completed |
NCT00521300 -
Preoperative Octreotide Treatment of Acromegaly
|
Phase 4 | |
| Completed |
NCT03548415 -
Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
|
Phase 2 | |
| Not yet recruiting |
NCT04066569 -
Reproducibility and Utility of OGTT in Acromegaly
|
N/A | |
| Not yet recruiting |
NCT05298891 -
Hypoproteic Diet in Acromegaly
|
N/A | |
| Recruiting |
NCT04520646 -
A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
|
N/A | |
| Not yet recruiting |
NCT04529356 -
The TMS Treatment for Postoperative Headache in GH Tumor
|
N/A | |
| Active, not recruiting |
NCT03252353 -
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
|
Phase 3 |